SIRT2 and metabolic dysfunction-associated steatohepatitis: In the indicated stages of NASH progression, we observed a decreased level of SIRT2 in advanced fibrosis (F3) compared to earlier stages of fibrosis as well as healthy controls (Figure 6A,B).